The significance of VEGF-C/VEGFR-2 interaction in the neovascularization and prognosis of nephroblastoma (Wilms' tumour)

Histopathology

Volumn 50, Issue 3, 2007, Pages 358-364

  Nowicki, M ^a   Ostalska Nowicka, D ^a   Kaczmarek, M ^a   Miskowiak, B ^a   Witt, M ^b  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Immunohistochemistry; Neovascularization; VEGF C; VEGFR 2; Wilms' tumour

Indexed keywords

VASCULOTROPIN C; VASCULOTROPIN RECEPTOR 2;

ANTIANGIOGENIC ACTIVITY; ARTICLE; BLASTEMA; CANCER CENTER; CANCER MORTALITY; CANCER TISSUE; CARCINOGENESIS; CELL SURFACE; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DYSPLASIA; EPITHELIUM CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MORPHOGENESIS; NEOVASCULARIZATION (PATHOLOGY); NEPHROBLASTOMA; OBSERVATION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN INTERACTION; RISK FACTOR; STATISTICAL SIGNIFICANCE; STROMA CELL; SURVIVAL RATE; TUMOR VASCULARIZATION;

CHILD; CHILD, PRESCHOOL; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS; IMMUNOENZYME TECHNIQUES; KIDNEY NEOPLASMS; NEOPLASM STAGING; NEOVASCULARIZATION, PATHOLOGIC; POLAND; PROGNOSIS; RISK FACTORS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR C; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; WILMS TUMOR;

EID: 33846543890     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2007.02613.x     Document Type: Article

References (43)

1. Maitra A, Kumar V. Diseases of infancy and childhood. In Kumar V, Abbas AK, Fausto N eds. Pathologic basis of diseases (Robbins and Cotran), 7th edn. Philadelphia: Elsevier Saunders 2005; 504-506.
2. Anderson PM. Neoplasms of the kidney. In Behrman RE, Kliegman R, Jenson HB eds. Textbook of pediatrics (Nelson), 16th edn. Philadelphia: W.B. Saunders Co. 2000; 1554-1556.
3. Groot-Loonen JJ, Pinkerton CR, Morris-Jones PH et al. How curable is relapsed Wilms' tumour? The United Kingdom children's cancer Study Group. Arch. Dis. Child. 1990; 65; 968-970.
4. Tammela T, Enholm B, Alitalo K, Paavonen K. The biology of vascular endothelial growth factors. Cardiovasc. Res. 2005; 65; 550-563.
5. Ferrara N, Gerber H-P, LeCouter J. The biology of VEGF and its receptors. Nat. Med. 2003; 9; 669-676.
6. Senger D, Van De Water L, Brown LF et al. Vascular permeability factor (VPF, VEGF) in tumour biology. Cancer Metastasis Rev. 1993; 12; 303-324.
7. Ghanem MA, van Steenbrugge GJ, Sudaryo MK et al. Expression and prognostic relevance of vascular endothelial growth factor (VEGF) and its receptor (FLT-1) in nephroblastoma. J. Clin. Pathol. 2003; 56; 107-113.
8. Karihaloo A, Karumanchi A, Cantley WL et al. Vascular endothelial growth factor induces branching morphogenesis/tubulogenesis in renal epithelial cells in a neuropilin-dependent fashion. Mol. Cell. Biol. 2005; 25; 7441-7448.
9. Villegas G, Lange-Sperandio B, Tufro A. Autocrine and paracrine functions of vascular endothelial growth factor (VEGF) in renal tubular epithelial cells. Kidney Int. 2005; 67; 449-457.
10. Saharinen P, Tammla T, Karkkainen MJ et al. Lymphatic vasculature: development, molecular regulation and role in tumor metastasis and inflammation. Trends Immunol. 2004; 25; 387-395.
11. Karkkainen MJ, Haiko P, Sainio K et al. Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins. Nat. Immunol. 2004; 5; 74-80.
12. Kukk E, Lymboussaki A, Taira S et al. VEGF-C receptor binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular development. Development 1996; 122; 3829-3837.
13. Lymboussaki A, Olofsson B, Eriksson U et al. Vascular endothelial growth factor (VEGF) and VEGF-C show overlapping binding sites in embryonic endothelia and distinct sites in differentiated adult endothelia. Circ. Res. 1999; 85; 992-999.
14. Matsumoto T, Claesson-Welsh L. VEGF receptor signal transduction. Sci. STKE 2001; 112; 1-17.
15. Shalaby F, Rossant TP, Yamaguchi M et al. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 1995; 376; 62-66.
16. Tournade MF, Com-Nougué C, de Kraker J et al. Optimal duration of preoperative therapy in unilateral and nonmetastatic Wilms' tumor in children older than 6 months: results of the Ninth International Society of Pediatric Oncology Wilms' Tumor Trial and Study. J. Clin. Oncol. 2001; 19; 488-500.
17. Pillai G, Cook N, Turley H et al. The expression and cellular localization of phosphorylated VEGFR2 in lymphoma and non-neoplastic lymphadenopathy: an immunohistochemical study. Histopathology 2005; 46; 209-216.
18. Armitage P. Statistical methods in medical investigations (in Polish), 1st edn. Warszawa: PZWL 1978; 97-103.
19. Folkman J. What is the evidence that tumors are angiogenesis dependent? J. Natl Cancer Inst. 1990; 82; 4-6.
20. Gunningham SP, Currie MJ, Han C et al. Vascular endothelial growth factor-B and vascular endothelial growth factor-C expression in renal cell carcinomas: regulation by the von Hippel-Lindau gene and hypoxia. Cancer Res. 2001; 61; 3206-3211.
21. Nicosia RF. What is the role of vascular endothelial growth factor-related molecules in tumor angiogenesis? Am. J. Pathol. 1998; 153; 11-16.
22. Barleon B, Sozzani S, Zhou D et al. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood 1996; 87; 3336-3343.
23. Kanellis J, Fraser S, Katerelos M, Power DA. Vascular endothelial growth factor is a survival factor for renal tubular epithelial cells. Am. J. Physiol. Renal Physiol. 2000; 278; F905-F915.
24. Takahashi T, Shirasawa T, Miyake K et al. Protein tyrosine kinases expressed in glomeruli and cultured glomerular cells: Flt-1 and VEGF expression in renal mesangial cells. Biochem. Biophys. Res. Commun. 1995; 209; 218-226.
25. Sandner P, Wolf K, Bergmaier U et al. Induction of VEGF and VEGF receptor gene expression by hypoxia: divergent regulation in vivo and in vitro. Kidney Int. 1997; 51; 448-453.
26. Ergun S, Kilic N, Fiedler W, Mukhopadhyay AK. Vascular endothelial growth factor and its receptors in normal human testicular tissue. Mol. Cell. Endocrinol. 1997; 131; 9-20.
27. Das SK, Chakraborty I, Wang J et al. Expression of vascular endothelial growth factor (VEGF) and VEGF-receptor messenger ribonucleic acids in the peri-implantation rabbit uterus. Biol. Reprod. 1997; 56; 1390-1399.
28. Midy V, Plouet J. Vasculotropin/vascular endothelial growth factor induces differentiation in cultured osteoblasts. Biochem. Biophys. Res. Commun. 1994; 199; 380-386.
29. Guerrin M, Moukadiri H, Chollet P et al. Vasculotropin/vascular endothelial growth factor is an autocrine growth factor for human retinal pigment epithelial cells cultured in vitro. J. Cell Physiol. 1995; 164; 385-394.
30. Rooman I, Schuit F, Bouwens L. Effect of vascular endothelial growth factor on growth and differentiation of pancreatic ductal epithelium. Lab. Invest. 1997; 76; 225-232.
31. Brown LF, Detmar M, Tognazzi K et al. Uterine smooth muscle cells express functional receptors (flt-1 and KDR) for vascular permeability factor/vascular endothelial growth factor. Lab. Invest. 1997; 76; 245-255.
32. Bacic M, Edwards NA, Merrill MJ. Differential expression of vascular endothelial growth factor (vascular permeability factor) forms in rat tissues. Growth Factors 1995; 2; 11-15.
33. Breier G, Albrecht U, Sterrer S, Risau W. Expression of vascular endothelial growth factor during embryonic angiogenesis and endothelial cell differentiation. Development 1992; 114; 521-532.
34. Peters KG, De Vries C, Williams LT. Vascular endothelial growth factor receptor expression during embryogenesis and tissue repair suggests a role in endothelial differentiation and blood vessel growth. Proc. Natl Acad. Sci. USA 1993; 90; 8915-8919.
35. Tufro A, Norwood VF, Carey RM, Gomez RA. Vascular endothelial growth factor induces nephrogenesis and vasculogenesis. J. Am. Soc. Nephrol. 1999; 10; 2125-2134.
36. Kitamoto Y, Tokunaga H, Tomita K. Vascular endothelial growth factor is an essential molecule for mouse kidney development: glomerulogenesis and nephrogenesis. J. Clin. Invest. 1997; 99; 2351-2357.
37. Mattot V, Moons L, Lupu F et al. Loss of the VEGF(164) and VEGF(188) isoforms impairs postnatal glomerular angiogenesis and renal arteriogenesis in mice. J. Am. Soc. Nephrol. 2002; 13; 1548-1560.
38. Tufro A. VEGF spatially directs angiogenesis during metanephric development in vitro. Dev. Biol. 2000; 227; 558-566.
39. Eremina V, Sood M, Haigh J et al. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J. Clin. Invest. 2003; 111; 707-716.
40. Maynard SE, Min JY, Merchan J et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J. Clin. Invest. 2003; 111; 649-658.
41. Ono M, Sawa Y, Matsumoto K et al. In vivo gene transfection with hepatocyte growth factor via the pulmonary artery induces angiogenesis in the rat lung. Circulation 2002; 106; I264-I269.
42. Strohmeyer D, Strauss F, Rossing C et al. Expression of bFGF, VEGF and c-met and their correlation with microvessel density and progression in prostate carcinoma. Anticancer Res. 2004; 24; 1797-1804.
43. Karihaloo A, Karumanchi SA, Barasch J et al. Endostatin regulates branching morphogenesis of renal epithelial cells and ureteric bud. Proc. Natl Acad. Sci. USA 2001; 98; 12509-12514.